Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Trial Profile

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs CBP 501 (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors CanBas
  • Most Recent Events

    • 14 Jan 2019 Planned number of patients changed from 42 to 48.
    • 14 Jan 2019 Planned End Date changed from 1 Mar 2019 to 30 Mar 2020.
    • 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 31 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top